Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
Philipp Koehler
(1)
,
Matteo Bassetti
(2)
,
Arunaloke Chakrabarti
,
Sharon C A Chen
(3)
,
Arnaldo Lopes Colombo
(4)
,
Martin Hoenigl
(5)
,
Nikolay Klimko
,
Cornelia Lass-Flörl
,
Rita O Oladele
(6)
,
Donald C Vinh
(7)
,
Li-Ping Zhu
(8)
,
Boris Böll
(1)
,
Roger Brüggemann
(9)
,
J.-P. Gangneux
(10)
,
John R Perfect
(11)
,
Thomas F Patterson
(12)
,
Thorsten Persigehl
(1)
,
Jacques F Meis
(13, 9)
,
Luis Ostrosky-Zeichner
(14)
,
P Lewis White
,
Paul E Verweij
(9)
,
Oliver A Cornely
(1)
1
Faculty of Medicine [Cologne]
2 UniGe - Università degli studi di Genova = University of Genoa
3 The University of Sydney
4 Universidade Federal de São Paulo
5 UC San Diego - University of California [San Diego]
6 University of Lagos
7 MUHC - McGill University Health Center [Montreal]
8 Shanghai Medical College, Fundan University [Shanghai China]
9 Radboud University Medical Center [Nijmegen]
10 Irset - Institut de recherche en santé, environnement et travail
11 Duke University Medical Center
12 University of Texas Health Science Center
13 UTFPR - Universidade Tecnológica Federal do Paraná [Curitiba, Brasil] = Federal Technological University of Paraná [Curitiba, Brazil] = Université technologique fédérale du Paraná [Curitiba, Brésil]
14 UTHealth - The University of Texas Health Science Center at Houston
2 UniGe - Università degli studi di Genova = University of Genoa
3 The University of Sydney
4 Universidade Federal de São Paulo
5 UC San Diego - University of California [San Diego]
6 University of Lagos
7 MUHC - McGill University Health Center [Montreal]
8 Shanghai Medical College, Fundan University [Shanghai China]
9 Radboud University Medical Center [Nijmegen]
10 Irset - Institut de recherche en santé, environnement et travail
11 Duke University Medical Center
12 University of Texas Health Science Center
13 UTFPR - Universidade Tecnológica Federal do Paraná [Curitiba, Brasil] = Federal Technological University of Paraná [Curitiba, Brazil] = Université technologique fédérale du Paraná [Curitiba, Brésil]
14 UTHealth - The University of Texas Health Science Center at Houston
Philipp Koehler
- Fonction : Auteur
- PersonId : 797224
- ORCID : 0000-0002-7386-7495
Matteo Bassetti
- Fonction : Auteur
- PersonId : 911731
Arunaloke Chakrabarti
- Fonction : Auteur
- PersonId : 792446
- ORCID : 0000-0003-1555-3807
Martin Hoenigl
- Fonction : Auteur
- PersonId : 765307
- ORCID : 0000-0002-1653-2824
Nikolay Klimko
- Fonction : Auteur
Cornelia Lass-Flörl
- Fonction : Auteur
- PersonId : 775497
- ORCID : 0000-0002-2946-7785
P Lewis White
- Fonction : Auteur
Résumé
Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.